Abivax SA (ABVX)
87.01
-1.21
(-1.37%)
USD |
NASDAQ |
Oct 07, 16:00
87.95
+0.94
(+1.08%)
After-Hours: 20:00
Abivax Total Liabilities (Quarterly) : 109.69M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 109.69M |
| March 31, 2026 | 135.44M |
| December 31, 2025 | 151.66M |
| Date | Value |
|---|---|
| September 30, 2025 | 165.46M |
| June 30, 2025 | 197.11M |
| March 31, 2025 | 187.45M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 302.16M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 528.44M |
| Shareholders Equity (Quarterly) | 418.75M |
| Debt to Equity Ratio | 0.0033 |
| Current Ratio | 5.965 |
| Net Debt Paydown Yield | 0.19% |